Background: At the 13th St Gallen International Breast Cancer Conference in 2013, a new definition of luminal A-like and luminal B-like breast cancer was proposed, involving the expression of estrogen receptor (ER), progesterone receptor (PgR), and Ki-67. We examined the rate of concordance between the risk groups using the Oncotype DX recurrence score (RS) and the previous and newly proposed luminal subtypes with the standardized Ki-67 assessment. Method: The relationship between a previously and newly proposed, immunohistochemically defined luminal A and B subtype with the Oncotype DX RS of 41 cases of T1-2 N0-1 M0 (ER positive, HER2 negative) breast cancer was assessed. We first classified the patients into the previously defined luminal A and B subtypes, according to the level of Ki-67 as either “low” (<14%) or “high” (≥14%), as assessed by local pathologists. Next, to consider the necessity for standardizing Ki-67 measurement methods, we re-examined Ki-67 with a central review. By introducing PgR positivity (≥20%), we classified these patients to newly proposed luminal subtypes and compared them with the risk groups stratified by Oncotype DX RS. Results: In the previously proposed luminal subtypes, the concordance rate between luminal A and the low RS category was 76.5% according to local pathologists and 90.1% by central review, whereas the rate between luminal B and the intermediate to high RS category was 46.7% and 45.8%, respectively. In newly proposed luminal subtypes, the concordance rate between luminal A and low RS category was 100% and between the luminal B and intermediate to high RS category was 53.6%. Conclusions: Although this study was based on a retrospective chart review of a small sample size, the newly proposed luminal subtypes including addition of PgR positivity with the standardized Ki-67 assessment appeared to improve the concordance rate especially between luminal A and low RS category.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of Chemotherapy and Hormonal Therapy for Early Breast Cancer on Recurrence and 15-Year Survival: An Overview of the Randomised Trials. Lancet, 365, 1687-1717. http://dx.doi.org/10.1016/S0140-6736(05)66544-0
Prat, A., Pineda, E., Adamo, B., et al. (2015) Clinical Implications of the Intrinsic Molecular Subtypes of Breast Cancer. Breast, 24, S26-S35. http://dx.doi.org/10.1016/j.breast.2015.07.008
Lopez, F., Belloc, F., Lacombe, F., et al. (1991) Modalities of Synthesis of Ki-67 Antigen during the Stimulation of Lymphocytes. Cytometry, 12, 42-49. http://dx.doi.org/10.1002/cyto.990120107
Urruticoechea, A., Smith, I.E. and Dowsett, M. (2005) Proliferation Marker Ki-67 in Early Breast Cancer. Journal of Clinical Oncology, 23, 7212-7220. http://dx.doi.org/10.1200/JCO.2005.07.501
Trihia, H., Murray, S., Price, K., et al. (2003) Ki-67 Expression in Breast Carcinoma: Its Association with Grading Systems, Clinical Parameters, and Other Prognostic Factors—A Surrogate Marker? Cancer, 97, 1321-1331. http://dx.doi.org/10.1002/cncr.11188
Spyratos, F., Ferrero-Pous, M., Trassard, M., et al. (2002) Correlation between MIB-1 and Other Proliferation Markers: Clinical Implications of the MIB-1 Cutoff Value. Cancer, 94, 2151-2159. http://dx.doi.org/10.1002/cncr.10458
Cheang, M.C., Chia, S.K., Voduc, D., et al. (2009) Ki67 Index, HER2 Status, and Prognosis of Patients with Luminal B Breast Cancer. Journal of the National Cancer Institute, 101, 736-750. http://dx.doi.org/10.1093/jnci/djp082
Bouzubar, N., Walker, K.J., Griffiths, K., et al. (1989) Ki67 Immunostaining in Primary Breast Cancer: Pathological and Clinical Associations. British Journal of Cancer, 59, 943-947. http://dx.doi.org/10.1038/bjc.1989.200
Dowsett, M., Nielsen, T.O., A’Hern, R., et al. (2011) Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. Journal of the National Cancer Institute, 103, 1656-1664. http://dx.doi.org/10.1093/jnci/djr393
Dowsett, M., Cuzick, J., Wale, C., et al. (2010) Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients with Breast Cancer Treated with Anastrozole or Tamoxifen: A Trans ATAC Study. Journal of Clinical Oncology, 28, 1829-1834. http://dx.doi.org/10.1200/JCO.2009.24.4798
Paik, S., Tang, G., Shak, S., et al. (2006) Gene Expression and Benefit of Chemotherapy in Women with Node-Negative, Estrogen Receptor—Positive Breast Cancer. Journal of Clinical Oncology, 24, 3726-3734. http://dx.doi.org/10.1200/JCO.2005.04.7985
Chen, C., Dhanda, R., Tseng, W.-T., et al. (2013) Evaluating Use Characteristics for the Oncotype Dx 21-Gene Recurrence Score and Concordance with Chemotherapy Use in Early-Stage Breast Cancer. Journal of Oncology Practice/ American Society of Clinical Oncology, 9, 182-187. http://dx.doi.org/10.1200/JOP.2012.000638
Sparano, J.A. and Paik, S. (2008) Development of the 21-Gene Assay and Its Application in Clinical Practice and Clinical Trials. Journal of Clinical Oncology, 26, 721-728. http://dx.doi.org/10.1200/JCO.2007.15.1068
Tang, G., Cuzick, J., Costantino, J.P., et al. (2011) Risk of Recurrence and Chemotherapy Benefit for Patients with Node-Negative, Estrogen Receptor—Positive Breast Cancer: Recurrence Score Alone and Integrated with Pathologic and Clinical Factors. Journal of Clinical Oncology, 29, 4365-4372.
Mamounas, E.P., Tang, G., Fisher, B., et al. (2010) Association between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor—Positive Breast Cancer: Results from NSABP B-14 and NSABP B-20. Journal of Clinical Oncology, 28, 1677-1683. http://dx.doi.org/10.1200/JCO.2009.23.7610
Dowsett, M., Ebbs, S.R., Dixon, J.M., et al. (2005) Biomarker Changes during Neoadjuvant Anastrozole, Tamoxifen, or the Combination: Influence of Hormonal Status and HER-2 in Breast Cancer—A Study from the IMPACT Trialists. Journal of Clinical Oncology, 23, 2477-2492. http://dx.doi.org/10.1200/JCO.2005.07.559
Harris, L., Fritsche, H., Mennel, R., et al. (2007) American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer. Journal of Clinical Oncology, 25, 5287-5312. http://dx.doi.org/10.1200/JCO.2007.14.2364
National Comprehensive Cancer Network Practice Guidelines in Oncology. Breast Cancer (Version v2.2011). http://www.NCCN.org
Aebi, S., Davidson, T., Gruber, G., et al. (2010) Primary Breast Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 21, v9-v14. http://dx.doi.org/10.1093/annonc/mdq159
Goldhirsch, A., Wood, C. and Coates, A.S. (2011) Strategies for Subtypes—Dealing with the Diversity of Breast Cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of Oncology, 22, 1736-1747. http://dx.doi.org/10.1093/annonc/mdr304
Goldhirsch, A., Ingle, J.N., Gelber, R.D., et al. (2009) Thresholds for Therapies: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. Annals of Oncology, 20, 1319-1329. http://dx.doi.org/10.1093/annonc/mdp322
Prat, A., Cheang, M.G.U., Martín, M., et al. (2013) Prognostic Significance of Progesterone Receptor—Positive Tumor Cells within Immunohistochemically Defined Luminal A Breast Cancer. Journal of Clinical Oncology, 31, 203-209. http://dx.doi.org/10.1200/JCO.2012.43.4134
Mizuno, Y., Natori, T., Takeda, N., et al. (2012) The Reliability of Assessment of Ki-67 Expression on Core Needle Biopsy and the Surgical Specimens of Invasive Breast Cancer: Comparison of Local Pathologists’ Assessment and Central Review. Journal of Cancer Therapy, 3, 841-845. http://dx.doi.org/10.4236/jct.2012.325107
Mizuno, Y., Fuchikami, H., Takeda, N., et al. (2014) Standardized Assessment of Ki-67 in Breast Cancer Patients Using Virtual Slides and an Automated Analyzer in Comparison to Central/Local Pathological Assessments. Journal of Cancer Therapy, 5, 141-146. http://dx.doi.org/10.4236/jct.2014.52017
Tang, P., Wang, J., Hicks, D.G., et al. (2010) A Lower Allred Score for Progesterone Receptor Is Strongly Associated with a Higher Recurrence Score of 21-Gene Assay in Breast Cancer. Cancer Investigation, 28, 978-982. http://dx.doi.org/10.3109/07357907.2010.496754
Sahebjam, S., Aloyz, R., Pilavdzic, D., et al. (2011) Ki 67 Is a Major, But Not the Sole Determinant of Oncotype DX Recurrence Score. British Journal of Cancer, 105, 1342-1345. http://dx.doi.org/10.1038/bjc.2011.402